| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.02. | Bolt Projects to delist from Nasdaq, deregister with SEC | 3 | Seeking Alpha | ||
| 19.02. | Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration | 921 | Business Wire | BERKELEY, Calif.--(BUSINESS WIRE)--Bolt Projects Holdings, Inc. (OTC Pink: BSLK, BSLKW), a developer of biomaterials for the beauty and personal care industry, today announced that its Board of Directors... ► Artikel lesen | |
| 05.01. | NASDAQ: Delisting von Bolt Projects Holdings nach Nichterfüllung der Eigenkapitalanforderungen | 1 | Investing.com Deutsch | ||
| 05.01. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Bolt Projects Holdings GAAP EPS of -$2.70, revenue of $0.37M | 1 | Seeking Alpha | ||
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.25 | Bolt Projects announces prelim Q3 results and updates 2025 guidance | 1 | Seeking Alpha | ||
| 17.10.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.09.25 | Bolt Projects registers 20M shares for potential sale under $20M equity line | 2 | Seeking Alpha | ||
| 26.09.25 | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.09.25 | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08.25 | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 836 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 17.07.25 | Pre-market Movers: Volcon, Bolt Projects, 22nd Century Group, Above Food Ingredients, Windtree Therapeutics | 982 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.25 A.M. ET).In the Green Volcon, Inc. (VLCN) is up over 161% at $24.11.
Bolt... ► Artikel lesen | |
| 30.05.25 | Pre-market Movers: Bolt Projects, Basel Medical Group, Red Robin Gourmet Burgers, LZ Technology, Medicus Pharma | 1.253 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.55 A.M. ET).In the Green Bolt Projects Holdings, Inc. (BSLK) is up over 114%... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 1,835 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,058 | +5,50 % | SOL Global Investments Corp.: SOL Global Announces Leadership Transition and Grant of PSUs | Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), today announced that Mr. Davide Marcotti has resigned... ► Artikel lesen | |
| TRINITY BIOTECH | 0,705 | -2,23 % | Trinity Biotech plc: Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives | - Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovation... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,260 | -5,58 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,140 | -2,16 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,390 | -1,42 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| CABALETTA BIO | 3,265 | -6,31 % | Cabaletta Bio-Aktie: Wird sie 2026 erneut zum Biotech-Highflyer? | Die Aktie des ehemaligen sharedeals.de-Tenbaggers Cabaletta Bio wird seit geraumer Zeit wieder mit vorsichtigem Optimismus begleitet, während das Biotech-Unternehmen versucht, eine gentechnisch veränderte... ► Artikel lesen | |
| LONGEVERON | 0,541 | -7,26 % | Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell | MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic... ► Artikel lesen | |
| VOR BIOPHARMA | 15,310 | -4,73 % | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| QIAGEN | 41,960 | +1,38 % | BARCLAYS stuft QIAGEN NV auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen mit einem Kursziel von 58 US-Dollar auf "Overweight" belassen. Dies schrieb Analyst Luke Sergott in seinem... ► Artikel lesen | |
| EVOTEC | 5,880 | +0,38 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| ARCELLX | 113,86 | +0,01 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| BIONTECH | 92,65 | +0,49 % | BioNTech Aktie: Steht die lange Post-COVID-Baisse vor ihrem Ende? | Hoch spannende Lage bei der BioNTech Aktie: Ein Doppel-Support aus der 50- und 200-Tage-Linie hat die jüngste Abwärtsbewegung gebremst. Während der Aktienkurs des Mainzer Biotech-Unternehmens an der... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,065 | -2,79 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| CARDIO DIAGNOSTICS | 7,070 | +33,40 % | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report |